Dalton Receives Approval for Cannabis Analytical Testing License

Dalton Pharma Services is pleased to announce its recent approval of Health Canada’s Cannabis Analytical Testing License under the Cannabis Act and Cannabis Regulations.

Dalton Pharma Services is pleased to announce its recent approval of Health Canada’s Cannabis Analytical Testing License under the Cannabis Act and Cannabis Regulations.

The Cannabis Act and Cannabis Regulations provide a basis for legal access to cannabis, including the control and regulation of cannabis through the production, distribution and sale processes. The cannabis analysis license is required to test cannabis for analysis by any means, including with an organic solvent. Cannabis analytical testing may include, but is not limited to, testing for chemical contaminants, microbial contaminants, cannabinoid content, dissolution or disintegration, and/or stability testing.

Currently, Dalton also holds the Cannabis Drug License (CDL) and Standard Processing License (SPL). CDL holders are permitted to sell medicinal products containing cannabis to other CDL holders, pharmacists, practitioners, hospital employees, researchers and analytical testers, while SPL is required for herbal cannabis products . Together, these two licenses allow the manufacture of recreational and medical cannabis products respectively.

The recently acquired Cannabis Analytical Testing License allows Dalton to perform testing related to cannabis products for our clients. This exciting development for Dalton Pharma Services enables the organization to perform cannabis product testing for products manufactured by Dalton and third-party testing contracts. All CBD herbal tests can now be performed in quality control laboratories.

About Dalton Pharma Services:

Dalton Pharma Services is a leading North American cGMP pharmaceutical organization providing integrated drug discovery, development and manufacturing services. We are FDA registered, Health Canada approved and bring over 35 years of experience to every project. We provide fully integrated solutions with an emphasis on speed, flexibility and quality. Our integrated services (drug discovery, formulation and process development, custom synthesis, cGMP sterile filling/finishing of liquids and powders, cGMP API manufacturing; dosage form manufacturing and accelerated stability testing) all at one location help to be adaptable, flexible and economical -efficient.

To learn more about our history and capabilities, please visit http://www.dalton.com.

Pierre Pekos

CEO

Dalton Pharmaceutical Services

349 Wildcat Road

Toronto, Ontario

Tel: 416-661-2102

Share the article on social networks or by e-mail: